The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study
Open accessAbstract
Twenty-one adult patients were randomised to receive ghrelin on days 1 and 8 and placebo on days 4 and 11 or vice versa, given intravenously over a 60-min period before lunch: 10 received 2 microg kg(-1) (lower-dose) ghrelin; 11 received 8 microg kg(-1) (upper-dose) ghrelin. Active and total ghrelin, growth hormone (GH), and insulin-like growth factor 1 levels were monitored at baseline (4-5 days before day 1), during treatment days, and at end of study (day 17/18). Drug-related adverse events (assessed by NCI-CTC-toxicity criteria and cardiac examination) did not differ between ghrelin and placebo. No grade 3/4 toxicity or stimulation of tumour growth was observed. The peak increase of GH, a biological marker of ghrelin action, was 25 ng ml(-1) with lower-dose and 42 ng ml(-1) with upper-dose ghrelin. Morning fasting total ghrelin levels were higher (P<0.05) for upper-dose patients at end of study (3580 pg ml(-1)) than at baseline (990 pg ml(-1)). Insulin-like growth factor 1 levels did not change. At day 8, 81% of patients preferred ghrelin to placebo as against 63% at the end of study. Nutritional intake and eating-related symptoms, measured to explore preliminary efficacy, did not differ between ghrelin and placebo. Ghrelin is well tolerated and safe in patients with advanced cancer. For safety, tolerance, and patients' preference for treatment, no difference was observed between the lower- and upper-dose group.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ghrelin is a growth-hormone-releasing acylated peptide from stomach
Kojima, M., Hosoda, H., Date, Y., Nakazato, M., Matsuo, H., & Kangawa, K. (1999) · Nature · doi:10.1038/45230 · Cited by 8,479
Abizaid, A., Liu, Z.-W., Andrews, Z. B., Shanabrough, M., Borok, E., Elsworth, J. D., Roth, R. H., Sleeman, M. W., Picciotto, M. R., Tschöp, M. H., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29867 · Cited by 984
Self-citationGhrelin action in the brain controls adipocyte metabolism
Theander-Carrillo, C. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25811 · Cited by 465
Schmid, D. A., Held, K., Ising, M., Uhr, M., Weikel, J. C., & Steiger, A. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300670 · Cited by 181
Cited by
Definition and classification of cancer cachexia: an international consensus
Fearon, K., Strasser, F., Anker, S. D., Bosaeus, I., Bruera, E., Fainsinger, R. L., Jatoi, A., Loprinzi, C., MacDonald, N., Mantovani, G., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70218-7 · Cited by 5,767
Self-citationESPEN guidelines on nutrition in cancer patients
Arends, J., Bachmann, P., Baracos, V., Barthelemy, N., Bertz, H., Bozzetti, F., Fearon, K., Hütterer, E., Isenring, E., Kaasa, S., et al. (2017) · Clinical Nutrition · doi:10.1016/j.clnu.2016.07.015 · Cited by 3,114
Self-citationDiagnostic Criteria for the Classification of Cancer-Associated Weight Loss
Martin, L., Senesse, P., Gioulbasanis, I., Antoun, S., Bozzetti, F., Deans, C., Strasser, F., Thoresen, L., Jagoe, R. T., Chasen, M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.1894 · Cited by 798
Self-citationNutritional interventions for cancer-induced cachexia
Gullett, N. P., Mazurak, V. C., Hebbar, G., & Ziegler, T. R. (2011) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2011.01.001 · Cited by 114
Treatment of cachexia: an overview of recent developments
von Haehling, S., & Anker, S. D. (2014) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2014.09.007 · Cited by 79
Metadata
- Authors
- Strasser, F., Lutz, T. A., Maeder, M. T., Thuerlimann, B., Bueche, D., Tschöp, M., Kaufmann, K., Holst, B., Brändle, M., von Moos, R., Demmer, R., & Cerny, T.
- Venue
- British Journal of Cancer
- Published
- 2008-01
- Volume
- 98
- Issue
- 2
- Pages
- 300-308
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2081246610
- Cited by
- 160
- References
- 4
- FWCI
- 6.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. https://app.cochat.ai/papers/10.1038/sj.bjc.6604148
- The paper
- Strasser, F., Lutz, T. A., Maeder, M. T., Thuerlimann, B., Bueche, D., Tschöp, M., Kaufmann, K., Holst, B., Brändle, M., von Moos, R., Demmer, R., & Cerny, T. (2008). Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6604148
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.